Age-Related Lymphocyte Output During Disease-Modifying Therapies for Multiple Sclerosis
ConclusionsThis observational study indicated that different age-related changes of the new T and B lymphocyte production could be one of the reasons for the emergence, in the real-world setting, of adverse events not otherwise observed in clinical trials; thus, caution is advised when choosing disease-modifying therapies for multiple sclerosis patients.
Source: Drugs and Aging - Category: Geriatrics Source Type: research
More News: Clinical Trials | Geriatrics | Gilenya | Multiple Sclerosis | Statistics | Study | Tysabri